ArticleAesthetic plastic surgery2026
Single-Session High-Dose Hyaluronidase for Managing Periorbital Hyaluronic Acid Filler Complications.
Article in Aesthetic plastic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hyaluronic Acid Fillers Versus Polynucleotides for Under-Eye Rejuvenation.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeriorbital complications from hyaluronic acid (HA) fillers are common due to the region's unique anatomy. Hyaluronidase is widely used for management, but dosing remains empirical with no standardized protocol. This study aimed to assess the safety and efficacy of a high-dose, single-session hyaluronidase approach for treating such complications.
methodsA retrospective study was conducted on 54 patients presenting with periorbital HA-related complications between August 2020 and May 2024. Four main types of complications were identified: persistent edema, tear trough bulging, under-correction, and subcutaneous nodules. The average interval from the first HA injection to presentation was 25.8 months (range 1.5-72 months). Injection points were determined through visual inspection and palpation, marked at the most prominent areas, and spaced approximately 7-10 mm apart. A vertical bolus injection technique was used to administer 30-90 IU (0.1-0.3 mL) of hyaluronidase per point, totaling 150-600 IU per lower eyelid.
resultsThe mean follow-up was 52.9 days (range 14-474 days). All patients responded successfully to one session of high-dose hyaluronidase. The mean dose per lower eyelid was 350.3 IU. No cases required retreatment. Nineteen patients (35.2%) achieved satisfactory outcomes without further intervention, while the remaining 35 (64.8%) underwent subsequent lower eyelid blepharoplasty.
conclusionHigh-dose, single-session hyaluronidase injection is a safe, effective, and efficient approach for treating a broad range of HA-related periorbital complications, even in complex cases involving multiple previous treatments or long filler retention time. LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
41145865What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.